Good, I’m almost out of #bananas nytimes.com/2022/10/17/sci…

Today, we announce a breakthrough in AI drug design: We’re the first to design AND validate new therapeutic antibodies with zero-shot #generativeAI. Read about it in our preprint: biorxiv.org/content/10.110… #JPM23

Trillion. With a T. #synbio Green industries could be worth $10.3 trln to economy by 2050 - study | Reuters reuters.com/business/susta…

Alex Phillipidis at @genbio does a great job of capturing what Absci does — and how it can go after the hardest part of the antibody with #generativeai and #synbio to create better #biologics for patients faster than ever. linkedin.com/posts/activity…

I adore you, @PlazaAccount Aubrey Plaza, but why are you propagandizing against sustainable milk? 💔

Thrilled to be back at @synbiobeta this year! You can always count on John Cumbers for a big start to a big event!

Creating drugs at the speed of Ai! ⁦Absci⁩ ⁦SynBioBeta⁩ ⁦Sean McClain⁩

E. coli is the unlikely hero of generative AI. Today it’s pharma, tomorrow it’s food, the next day it will be the stars! SynBioBeta Absci

You heard it here first: data is more important than models. Code to Cure panel moderated by Sean McClain . SynBioBeta Absci

What a strange and wonderful performance! Thank you @drewendy.bsky.social Michael Specter Ahmed Best. SynBioBeta

We are excited to announce our new collaboration with Almirall! We’ll be working together to develop and commercialize AI-designed therapeutics to fight chronic and debilitating dermatological diseases. investors.absci.com/news-releases/…

We're excited to announce our new collaboration with AstraZeneca! This collaboration combines Absci's Integrated Drug Creation™ platform with AstraZeneca's expertise in oncology with the goal of accelerating the discovery of a potential new cancer treatment candidate.

We Absci are excited to unveil IgDesign™ NeurIPS Conference and present our work at MLSB @ NeurIPS NeurIPS AI4D3 Workshop GenBio Workshop @ ICML25! IgDesign is an antibody inverse folding model that we have experimentally validated in our lab. Read the paper here: biorxiv.org/content/10.110… #NeurIPS2023

We’re excited to announce our new strategic partnership with PrecisionLife. Under the partnership, we’ll be working together to discover and develop a shared pipeline of biotherapeutics for up to five mutually agreed-upon targets and indications. investors.absci.com/news-releases/…

We’re back again, this time with details on our models for de novo design and new, open sourced data on functionality and developability, going beyond binding. We show one design has 3x higher potency than trastuzumab! Paper: biorxiv.org/content/10.110… Data: github.com/AbSciBio/unloc…